North America: Food, Drugs, Healthcare, Life Sciences

Subscribe
Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.
Article
Teva And Samsung Bioepis Enter Into Commercialization Agreement For OPUVIZ In Canada
Teva Pharmaceutical Industries and Samsung Bioepis have announced a strategic partnership to commercialize OPUVIZ, a biosimilar referencing EYLEA, in the Canadian market. The agreement divides responsibilities between Samsung Bioepis handling product registration and manufacturing while Teva Canada leads commercialization efforts. OPUVIZ has already received Health Canada approval for treating multiple eye conditions including wet age-related macular degeneration and diabetic macular edema.
Canada Healthcare
GP
Goodwin Procter LLP
Article
Payers, Providers, And Patients – Oh My!: The No Surprises Act's Independent Dispute Resolution Process & 2026 Updates (Podcast)
The No Surprises Act of 2021 aimed to shield patients from unexpected medical bills, but has the federal independent dispute resolution process it created lived up to its promise? This episode examines the challenges that have emerged, the new federal rule issued in June 2024, and the enforcement litigation landscape that continues to evolve.
United States Healthcare
CM
Crowell & Moring LLP
See more

Highlighted Content

Food and Drugs Law

Article
Teva And Samsung Bioepis Enter Into Commercialization Agreement For OPUVIZ In Canada
Teva Pharmaceutical Industries and Samsung Bioepis have announced a strategic partnership to commercialize OPUVIZ, a biosimilar referencing EYLEA, in the Canadian market. The agreement divides responsibilities between Samsung Bioepis handling product registration and manufacturing while Teva Canada leads commercialization efforts. OPUVIZ has already received Health Canada approval for treating multiple eye conditions including wet age-related macular degeneration and diabetic macular edema.
Canada Healthcare
GP
Goodwin Procter LLP
See more

Life Sciences, Biotechnology & Nanotechnology

See more

Healthcare

Article
Teva And Samsung Bioepis Enter Into Commercialization Agreement For OPUVIZ In Canada
Teva Pharmaceutical Industries and Samsung Bioepis have announced a strategic partnership to commercialize OPUVIZ, a biosimilar referencing EYLEA, in the Canadian market. The agreement divides responsibilities between Samsung Bioepis handling product registration and manufacturing while Teva Canada leads commercialization efforts. OPUVIZ has already received Health Canada approval for treating multiple eye conditions including wet age-related macular degeneration and diabetic macular edema.
Canada Healthcare
GP
Goodwin Procter LLP
Article
Payers, Providers, And Patients – Oh My!: The No Surprises Act's Independent Dispute Resolution Process & 2026 Updates (Podcast)
The No Surprises Act of 2021 aimed to shield patients from unexpected medical bills, but has the federal independent dispute resolution process it created lived up to its promise? This episode examines the challenges that have emerged, the new federal rule issued in June 2024, and the enforcement litigation landscape that continues to evolve.
United States Healthcare
CM
Crowell & Moring LLP
See more

Latest Videos

See more